Wedbush Maintains Outperform on Gossamer Bio, Lowers Price Target to $5
Portfolio Pulse from richadhand@benzinga.com
Wedbush analyst Andreas Argyrides maintains an Outperform rating on Gossamer Bio (NASDAQ:GOSS) but lowers the price target from $7 to $5.

July 26, 2023 | 12:38 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Wedbush maintains an Outperform rating on Gossamer Bio but lowers the price target from $7 to $5.
The lowered price target by Wedbush could potentially lead to a negative sentiment among investors, which might put downward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100